New drug combo shows promise against rare eye cancer
NCT ID NCT05170334
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining two drugs, binimetinib and belinostat, can shrink or stop the growth of metastatic uveal melanoma, a rare eye cancer that has spread. About 7 adults with this condition are taking part. The main goal is to see how many patients respond to the treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UVEAL MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drug duo tame a rare eye cancer that has spread?
- Can a new drug shrink Hard-to-Treat eye cancer?
- Double immunotherapy plus liver blockade targets eye cancer that spreads
- First-in-Class cancer drug targets Hard-to-Treat tumors
- Engineered immune cells take on Hard-to-Treat melanoma
- Immune cell therapy shows promise against rare eye cancer